Pill with imprint IP 102 IP 102 is Beige, Capsule/Oblong and has been identified as Gabapentin 300 mg. It is supplied by Amneal Pharmaceuticals.
Gabapentin is used in the treatment of Back Pain; Postherpetic Neuralgia; Epilepsy; Chronic Pain; Seizures and belongs to the drug class gamma-aminobutyric acid analogs. Risk cannot be ruled out during pregnancy. Gabapentin 300 mg is not a controlled substance under the Controlled Substances Act (CSA).
Gabapentin
- Imprint
- IP 102 IP 102
- Strength
- 300 mg
- Color
- Beige
- Size
- 19.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Gamma-aminobutyric acid analogs
- Pregnancy Category
- C – Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Amneal Pharmaceuticals
Labelers / Repackagers
| NDC Code | Labeler / Repackager |
|---|---|
| 53746-0102 (Discontinued) | Amneal Pharmaceuticals LLC |
| 65162-0102 | Amneal Pharmaceuticals LLC |
| 42291-0301 (Discontinued) | AvKare, Inc. |
| 63739-0689 (Discontinued) | McKesson Packaging Services |
| 63739-0236 | McKesson Packaging Services |
| 54868-5166 (Discontinued) | Physicians Total Care Inc. (repackager) |
| 53002-1423 | Pharmedix (repackager) |
| 33261-0049 | Aidarex Pharmacuticals, LLC (repackager) |
The efficacy of Gabapentin in the treatment of neuropathic pain has been demonstrated in several placebo-controlled studies. In a study involving 502 patients with neuropathic pain treated with Gabapentin at a dose of 300 to 1800 mg/day, efficacy was assessed by the percentage of patients who had a 50% or more reduction in pain. Gabapentin has been shown to be effective in 69% of patients receiving 900 or 1800 mg per day, and in 57% of patients taking 300-600 mg of Gabapentin. In approximately 80% of patients responding to therapy, the effect persisted after discontinuation of the drug.